Targeting autophagy in aortic aneurysm and dissection

Biomed Pharmacother. 2022 Sep:153:113547. doi: 10.1016/j.biopha.2022.113547. Epub 2022 Aug 15.

Abstract

Autophagy is a well-conserved biological process that maintains homeostasis. Accumulating evidence has revealed that autophagy plays an important role in various cardiovascular diseases, such as aneurysm, aortic dissection, atherosclerosis, and myocardial ischemia-reperfusion injury. Here, we summarize the current experimental evidence on the function of autophagy and autophagy proteins in aortic aneurysm and dissection (AAD). AAD is a very serious aortic disease, and there are currently no effective drug treatment options. Studies have shown that autophagy is activated during AAD. However, the role of autophagy in AAD is still controversial. For example, knocking out autophagy related 5 (ATG5) or ATG7 to inhibit autophagy and excessive autophagy activation can promote the occurrence of AAD. Recently, multiple studies have demonstrated that rapamycin and metformin, which are autophagy activators, can delay the progression of AAD. Thus, targeting autophagy has the potential to become a new therapeutic strategy for AAD. In addition, we discuss the recent research progress on AAD from the perspective of single-cell RNA sequencing. Moreover, we offer our perspective on current challenges and barriers in this research field.

Keywords: Aortic aneurysm; Aortic dissection; Autophagy; Metformin; Rapamycin; Single-cell RNA sequencing.

Publication types

  • Review

MeSH terms

  • Aortic Aneurysm* / drug therapy
  • Aortic Dissection* / drug therapy
  • Autophagy
  • Humans
  • Treatment Outcome